Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 2
2007 3
2008 6
2009 4
2010 6
2011 6
2012 2
2013 2
2014 7
2015 7
2016 4
2017 8
2018 7
2019 5
2020 10
2021 11
2022 3
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Results by year

Filters applied: . Clear all
Page 1
Optimal design of pharmacokinetic studies.
Aarons L, Ogungbenro K. Aarons L, et al. Among authors: ogungbenro k. Basic Clin Pharmacol Toxicol. 2010 Mar;106(3):250-5. doi: 10.1111/j.1742-7843.2009.00533.x. Epub 2010 Jan 20. Basic Clin Pharmacol Toxicol. 2010. PMID: 20102362 Free article. Review.
Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy.
Darwich AS, Polasek TM, Aronson JK, Ogungbenro K, Wright DFB, Achour B, Reny JL, Daali Y, Eiermann B, Cook J, Lesko L, McLachlan AJ, Rostami-Hodjegan A. Darwich AS, et al. Among authors: ogungbenro k. Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:225-245. doi: 10.1146/annurev-pharmtox-033020-113257. Epub 2020 Oct 9. Annu Rev Pharmacol Toxicol. 2021. PMID: 33035445 Review.
Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future.
Darwich AS, Ogungbenro K, Vinks AA, Powell JR, Reny JL, Marsousi N, Daali Y, Fairman D, Cook J, Lesko LJ, McCune JS, Knibbe C, de Wildt SN, Leeder JS, Neely M, Zuppa AF, Vicini P, Aarons L, Johnson TN, Boiani J, Rostami-Hodjegan A. Darwich AS, et al. Among authors: ogungbenro k. Clin Pharmacol Ther. 2017 May;101(5):646-656. doi: 10.1002/cpt.659. Epub 2017 Apr 4. Clin Pharmacol Ther. 2017. PMID: 28182269 Review.
Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug-Drug Interactions in Children.
Cleary Y, Kletzl H, Grimsey P, Heinig K, Ogungbenro K, Silber Baumann HE, Frey N, Aarons L, Galetin A, Gertz M. Cleary Y, et al. Among authors: ogungbenro k. Clin Pharmacokinet. 2023 Jun;62(6):891-904. doi: 10.1007/s40262-023-01241-7. Epub 2023 May 6. Clin Pharmacokinet. 2023. PMID: 37148485 Free PMC article.
Experimental designs for small randomised clinical trials: an algorithm for choice.
Cornu C, Kassai B, Fisch R, Chiron C, Alberti C, Guerrini R, Rosati A, Pons G, Tiddens H, Chabaud S, Caudri D, Ballot C, Kurbatova P, Castellan AC, Bajard A, Nony P; CRESim & Epi-CRESim Project Groups; Aarons L, Bajard A, Ballot C, Bertrand Y, Bretz F, Caudri D, Castellan C, Chabaud S, Cornu C, Dufour F, Dunger-Baldauf C, Dupont JM, Fisch R, Guerrini R, Jullien V, Kassaï B, Nony P, Ogungbenro K, Pérol D, Pons G, Tiddens H, Rosati A, Alberti C, Chiron C, Kurbatova P, Nabbout R. Cornu C, et al. Among authors: ogungbenro k. Orphanet J Rare Dis. 2013 Mar 25;8:48. doi: 10.1186/1750-1172-8-48. Orphanet J Rare Dis. 2013. PMID: 23531234 Free PMC article. Review.
Anakinra in COVID-19: important considerations for clinical trials.
King A, Vail A, O'Leary C, Hannan C, Brough D, Patel H, Galea J, Ogungbenro K, Wright M, Pathmanaban O, Hulme S, Allan S. King A, et al. Among authors: ogungbenro k. Lancet Rheumatol. 2020 Jul;2(7):e379-e381. doi: 10.1016/S2665-9913(20)30160-0. Epub 2020 May 21. Lancet Rheumatol. 2020. PMID: 32835233 Free PMC article. No abstract available.
86 results